Cascinu, Stefano <br/><br/>
Treatment sequence with either irinotecan/cetuximab followed by FOLFOX-4 or the reverse strategy in metastatic colorectal cancer patients progressing after first-line FOLFIRI/bevacizumab: An Italian Group for the Study of Gastrointestinal Cancer phase III, randomised trial comparing two sequences of therapy in colorectal metastatic patients.  [electronic resource] 

 -  European journal of cancer (Oxford, England : 1990)  09 2017 
 - 106-115 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial 
<br/><br/><label>ISSN: </label>1879-0852 
<br/><br/><label>Standard No.: </label>10.1016/j.ejca.2017.06.029  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Antibodies, Monoclonal, Humanized--administration & dosage<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Bevacizumab--administration & dosage<br/>Camptothecin--administration & dosage<br/>Carcinoma--drug therapy<br/>Cetuximab--administration & dosage<br/>Colorectal Neoplasms--drug therapy<br/>Disease-Free Survival<br/>Female<br/>Fluorouracil--administration & dosage<br/>Humans<br/>Irinotecan<br/>Kaplan-Meier Estimate<br/>Leucovorin--administration & dosage<br/>Male<br/>Middle Aged<br/>Organoplatinum Compounds--administration & dosage<br/>Oxaliplatin